ELOX - エロックス・ファ―マシュ―ティカルズ (Eloxx Pharmaceuticals Inc.) エロックス・ファ―マシュ―ティカルズ

 ELOXのチャート


 ELOXの企業情報

symbol ELOx
会社名 Eloxx Pharmaceuticals Inc (エロックス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Eloxx Pharmaceuticals Inc. formerly Sevion Therapeutics Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. The Company’s lead product candidate is ELX-02 is an optimized aminoglycoside designed to restore full-length functional proteins. The ELX-02 which is in Phase I clinical trial that focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. As part of clinical program the Company has completed a Phase Ia single ascending dose study in Israel and Belgium. The Company also intends to advance one or more additional molecules from its drug product candidate library toward clinical development.   エロックス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がんや免疫疾患に対する治療の開発・商業化に従事する。同社候補薬は細胞ベ―スのアレイ化抗体やキメラソ―ム・ナノケ―ジを含む。また、免疫疾患や炎症性疾患の病因であるKv1.3イオンチャネルや、がんの進行に関する分子を標的とする治療を開発する。本社はマサチュ―セッツ州ウォルサム。   Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx's lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx's preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx also has preclinical programs focused on kidney diseases including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel and Morristown, NJ.
本社所在地 950 Winter Street Waltham MA 02451 USA
代表者氏名 Robert E. Ward ロバートE.ウォード
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 858-909-0749
設立年月日 36161
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 15人
url www.senesco.com
nasdaq_url https://www.nasdaq.com/symbol/elox
adr_tso
EBITDA EBITDA(百万ドル) -40.95794
終値(lastsale) 14.91
時価総額(marketcap) 519728008.8
時価総額 時価総額(百万ドル) 522.51660
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 459.10460
当期純利益 当期純利益(百万ドル) -41.16942
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Eloxx Pharmaceuticals Inc revenues was not reported. Net loss totaled to $22M. Results are not comparable due to year end change.

 ELOXのテクニカル分析


 ELOXのニュース

   Eloxx Pharmaceuticals Announces Changes to Board of Directors  2022/07/05 12:00:00 GlobeNewswire
Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures
   The Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Stock Price: Is It Overvalued?  2022/06/25 12:30:00 Stocks Register
Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) shares, rose in value on Friday, 06/24/22, with the stock price down by -3.63% to the previous day’s close as strong demand from buyers drove the stock to $0.24. Actively observing the price movement in the last trading, the stock closed the session at $0.25, falling within a range of $0.2385 … The Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Stock Price: Is It Overvalued? Read More »
   Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Stock: Boom Or Bust? What Happens Next?  2022/06/04 19:00:00 Marketing Sentinel
During the last session, Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX)’s traded shares were 0.31 million, with the beta value of the company hitting 2.46. At the end of the trading day, the stock’s price was $0.31, reflecting an intraday loss of 0.58% or $0.0. The 52-week high for the ELOX share is $2.53, that puts it down … Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Stock: Boom Or Bust? What Happens Next? Read More »
   Eloxx Pharmaceuticals Inc. At $0.30: Buy, Sell Or Hold?  2022/05/28 14:00:00 Marketing Sentinel
Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX)’s traded shares stood at 0.37 million during the last session, with the company’s beta value hitting 2.37. At the close of trading, the stock’s price was $0.30, to imply a decrease of -4.81% or -$0.01 in intraday trading. The ELOX share’s 52-week high remains $2.53, putting it -743.33% down since that … Eloxx Pharmaceuticals Inc. At $0.30: Buy, Sell Or Hold? Read More »
   Eloxx Pharmaceuticals GAAP EPS of $0.13 beats by $0.24 (NASDAQ:ELOX)  2022/05/10 12:53:54 Seeking Alpha
Eloxx Pharmaceuticals press release (ELOX): Q1 GAAP EPS of $0.13 beats by $0.24.Cash and cash equivalents of $39.8M
   Eloxx to Test Its Lead Product Candidate, ELX-02, In Rare Kidney Disease  2022/03/31 17:21:22 Benzinga
Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) expanded the ELX-02 development program to include the treatment of Alport syndrome, a rare kidney disease. Clinical testing of ELX-02 in Alport syndrome is expected to initiate in 2H of 2022, with topline results expected in 1H of 2023. Alport syndrome is a genetic disorder characterized by kidney disease with high levels of proteinuria, hearing … Full story available on Benzinga.com
   Eloxx Pharmaceuticals GAAP EPS of -$0.14 misses by $0.02  2022/03/31 13:37:34 Seeking Alpha
Eloxx Pharmaceuticals press release (ELOX): Q4 GAAP EPS of -$0.14 misses by $0.02.As of December 31, 2021, cash and cash equivalents of $42.3 million
   Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update  2022/03/31 11:00:00 GlobeNewswire
Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022
   Eloxx Pharma to target Alport syndrome with lead candidate  2022/03/30 21:20:00 Seeking Alpha
Eloxx Pharmaceuticals (ELOX), a clinical-stage pharma company focused on RNA-modulating therapies for rare diseases announced on Wednesday that the company expanded its studies for the…
   Hot Stock to Observe: VYNE Therapeutics Inc. (NASDAQ:VYNE), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)  2022/03/24 01:46:51 Stock Equity
VYNE Therapeutics Inc. (NASDAQ:VYNE) with the stream of 1.66% also noticed, India Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) encountered a rapid change of 0.98% in the last hour of Wednesday’s trading session. … The post Hot Stock to Observe: VYNE Therapeutics Inc. (NASDAQ:VYNE), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) appeared first on Stocks Equity .
   Blustering Stock Grabbing Investors Attention: Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), Alibaba Group Holding Limited (NYSE:BABA)  2021/12/20 00:07:31 Stock Equity
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) with the stream of 12.06% also noticed, India Alibaba Group Holding Limited (NYSE:BABA) encountered a rapid change of 1.54% in the last hour of Fridays trading The post Blustering Stock Grabbing Investors Attention: Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), Alibaba Group Holding Limited (NYSE:BABA) appeared first on Stocks Equity .
   Eloxx Pharmaceuticals (NASDAQ:ELOX) Now Covered by Oppenheimer  2021/12/18 06:56:44 Transcript Daily
Investment analysts at Oppenheimer began coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a note issued to investors on Thursday, Price Targets.com reports. The brokerage set an outperform rating and a $4.00 price target on the stock. Oppenheimers price target suggests a potential upside of 441.27% from the stocks previous close. ELOX has been the []
   Glistering Stock: Sunworks, Inc. (NASDAQ:SUNW), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)  2021/12/16 00:30:26 Stock Equity
Sunworks, Inc. (NASDAQ:SUNW) with the stream of 3.22% also noticed, India Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) encountered a rapid change of 3.74% in the last hour of Wednesdays trading session. Sunworks, The post Glistering Stock: Sunworks, Inc. (NASDAQ:SUNW), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) appeared first on Stocks Equity .
   Millennium Management LLC Makes New Investment in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)  2021/12/13 09:24:42 Transcript Daily
Millennium Management LLC acquired a new position in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 393,703 shares of the companys stock, valued at approximately $783,000. Millennium Management LLC owned approximately 0.82% of Eloxx Pharmaceuticals at the end of the []
   Top RSI Trades for the day: New Oriental Education & Technology Group Inc. (NYSE:EDU), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)  2021/12/12 23:28:46 Stock Equity
New Oriental Education & Technology Group Inc. (NYSE:EDU) with the stream of 4.07% also noticed, India Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) encountered a rapid change of -5.41% in the last hour The post Top RSI Trades for the day: New Oriental Education & Technology Group Inc. (NYSE:EDU), Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) appeared first on Stocks Equity .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エロックス・ファ―マシュ―ティカルズ ELOX Eloxx Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)